Leukemia

During maintenance therapy for childhood ALL, there was a general increase in DNA-incorporated thioguanine nucleotides (DNA-TGN), and this increase was associated with a lower frequency of disease relapse.

As we learn more about the biology of AML, it appears that 7+3 only rarely clears residual leukemic clones in patients with higher-risk disease. New therapies are needed that can target and eradicate resistant subclones early in the disease course.

Adding rituximab to an escalated regimen of BEACOPP did not improve progression-free survival in patients with advanced-stage Hodgkin lymphoma.

The final, long-term analysis of the landmark IRIS study showed that imatinib’s efficacy persists over time in patients with CML, and no unacceptable late toxic or cumulative effects were observed.

We spoke with Dr. Anas Younes about the molecular characteristics of diffuse large B-cell lymphoma.

There is a critical need for new therapies for T-cell lymphomas, and with ongoing trials of mTOR and aurora kinase inhibitors, PI3K inhibitors, and others, new options may be on the horizon.

The emergence of ibrutinib-resistant chronic lymphocytic leukemia (CLL) can be detected prior to clinical relapse, according to an analysis of patients from four ibrutinib trials.

A handful of novel antibody-based therapies may soon emerge for the treatment of acute myeloid leukemia, according to a presentation at the 21st Annual International Congress on Hematologic Malignancies.

Cessation of second-generation TKIs yielded good treatment-free remission rates in patients with chronic myeloid leukemia who had sustained deep molecular responses.

Significant progress has been made in the treatment of chronic lymphocytic leukemia with the addition of options such as the tyrosine kinase inhibitor ibrutinib, the monoclonal antibody obinutuzumab, and the BCL2 inhibitor venetoclax.

Smoking is linked to mortality and to disease progression among patients with chronic myeloid leukemia.

Three courses of clofarabine combined with cytarabine may improve relapse-free survival in patients with acute myeloid leukemia in first remission.

Adolescents and young adults with leukemia experienced inferior outcomes compared with children, especially if they were treated outside of a specialized cancer center.

Patients with chronic lymphocytic leukemia who discontinue treatment with ibrutinib due to disease progression or transformation had significantly worse survival compared with patients who discontinued therapy because of intolerance.

Despite significant toxicities, idelalisib improved time to progression for patients with treatment-resistant chronic lymphocytic leukemia.

Combined miniCHOP and treatment with the fully-human anti-CD20 monoclonal antibody ofatumumab is associated with improved overall survival among elderly patients diagnosed with diffuse large B-cell lymphoma.

This video examines frontline treatment options for patients with newly diagnosed chronic lymphocytic leukemia, including considerations for when chemotherapy or ibrutinib might be more appropriate.

Stem cells that give rise to acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) express higher levels of the CD99 cell surface protein-sugar molecule than normal stem cells.

CML patients who have high expression of the T-cell inhibitory receptor (CTLA-4)-ligand CD86 on plasmacytoid dendritic cells have a higher risk of relapsing after discontinuing therapy with a tyrosine kinase inhibitor.

One of the confounding issues with treating patients with immunotherapy for hematologic diseases is the risk of relapse that can occur during and after treatment.

The addition of clofarabine to standard induction therapy for newly diagnosed acute myeloblastic leukemia reduced the probably of relapse but increased toxicity and had no effect on survival.

Here we critically analyze the role of PET/CT in the early assessment of Hodgkin lymphoma.

Presentation with musculoskeletal manifestations as the only symptom in pediatric B-cell acute lymphoblastic leukemia was significantly associated with diagnostic delay. However, this delay did not affect patient prognosis.

The use of minimal residual disease provided a more objective measure of induction failure in patients with pediatric acute lymphoblastic leukemia than did morphology.